Isotechnika Pharma Inc IPHAF

RE: Analysts

[stockman6]

""Please don't post such outrageous lies. "" LOL, I like that one weepee. Kinda like Heidi Fleiss extolling the virtues of chastity...... ""Compromising the immune system is very dangerous-period. That is why even IF the toxicity profile of ISAtx247 is proven to be low, its use will also be very restricted in autoimmune indications for only the most severe cases."" Hmmmm, I guess the great biotech guru weepee has the final word on immunosuppressants for psoriasis. Could you please forward the journals that you published your findings in. It would be very interesting article (although likely only about two lines!), because it is contrary to what has been published in the European Journal of Dermatology. Following is a summary of an article that was written, it seems that scientists are exited about the possibilities for immunosuppressants for psoriasis. Funny that they mention suggest LOW incidence and severity of adverse effects. Maybe you, the great biotech guru, could call them and explain what your research has proven? SUMMARY The treatment of dermatological disorders with macrolide immunosuppressants with a major emphasis on topical application will soon gain as much importance as the corticosteroids did decades ago. After the availiability of market formulations not only the topical therapy of the two major diseases psoriasis and atopic dermatitis will be changed dramatically, but also the treatment of nearly all inflammatory cutaneous disorders. High therapeutic efficacy, a low incidence and severity of adverse effects and the lack of atrophogenic potential will recommend macrolide immunosuppressants as the topical treatment of choice for the outlined indications.